Prévisions

Aucune donnée d'analyste n'est disponible pour cette entreprise.

Actualités Accéder au fil d'actualités

Innocan Pharma plans listing on NYSE American by Jan. 30

Innocan Pharma expects to be listed on the NYSE American by January 30, 2026, subject to approval and compliance with exchange rules. The company is simultaneously considering, depending on market conditions and regulatory approval, a concurrent offering of securities; details will be provided in SEC and SEDAR+ filings. Common shares are expected to continue trading on the OTCQB until the close of trading on or about January 29; trading on the CSE under the ticker INNO will remain in place. Innocan reports a market capitalization of roughly $19.72 million, more cash than debt, a current ratio of 3.72, and a share price trading near its 52-week low. » Plus sur de.investing.com
InnoCan Pharma reports Q3 EPS loss of CAD 0.49 and 20% revenue decline

For the quarter ended September 30, 2025, InnoCan Pharma reported an EPS loss of CAD 0.49 per share (year-ago: -CAD 0.090). Revenue fell to CAD 9.4 million from CAD 11.8 million in the year-ago quarter, a decline of 20.07%. The figures were presented at the financial conference for the quarter ended on November 26, 2025. » Plus sur finanzen.net

Au dernier trimestre, Innocan Pharma a réalisé un chiffre d'affaires de 5,51M€ et un bénéfice net de −828,08k€

Nom	Innocan Pharma
PDG	Iris Bincovich
Siège social	Calgary, ab Canada
Site web	innocanpharma.com
Secteur	Santé
Industrie	Prestataires et services de santé
Employés	11